Trial Profile
A retrospective study to evaluate the impact of Alemtuzumab on protective immunity in renal transplant patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 10 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress